← Back to screener

Autolus Therapeutics plc AUTL

Rank #2466 · Nasdaq · $0.4B market cap
⚠ Going-concern flag — the auditor (Ernst & Young LLP) raised substantial doubt about this company's ability to continue operating in the latest filing. Read the actual filing before drawing conclusions.
Score
15.8
P/E
-1.8
P/B
3.63
ROE
-197.9%
Op. Margin
-2385.6%
Debt Ratio
319%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Weak

P/E -1.8x, P/B 3.63x. Ranks in the top 76% of the universe.

Profitability ★☆☆☆☆
Poor

ROE -197.9%. Ranks in the top 97% of the universe.

Safety ★☆☆☆☆
Weak

Debt ratio 319%. Ranks in the top 73% of the universe. Above 200% signals meaningful leverage risk.

Growth ★★★★★
Excellent

Revenue growth of 496.0% year over year. Ranks in the top 1% of the universe.

Growth is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2023–$-0.1B$-0.1B$0.2B–44
2024$0.0B$-0.2B$-0.2B$0.3B-10583.188
2025$0.0B$-0.2B$-0.2B$0.1B-2385.6319

← See the full screener